[Taipei, June 15, 2023] Mycenax Biotech (hereinafter referred to as "Mycenax", TWO: 4726) announced today it has signed an MOU with StemCyte. StemCyte will become the cell therapy material supplier for Mycenax’s global allogeneic cell therapy CDMO business.
Mycenax, who is positioned as a "big D and medium M" CDMO, has been actively expanding into the field of cell therapy. With the signing of the MOU with StemCyte, the only multinational cell therapy company in Taiwan with its own allogeneic public cord blood bank resources, Mycenax will be able to provide customers with more sophisticated one-stop professional services in cell therapy.
Mycenax stated, "Mycenax is a CDMO company that expertise spans across both traditional and emerging biopharmaceuticals. Based on market trends and customer demands, Mycenax has developed technologies and production capabilities for both traditional and emerging biopharmaceuticals. In 2021, Mycenax established a team and laboratory dedicated to allogeneic cell therapy, focusing on advanced process development services for allogeneic stem cells and immune cells. The cell product categories include mesenchymal stem cells, chimeric antigen receptor natural killer cells (CAR-NK), gamma delta T cells (GDT), and mesenchymal stem cell-derived extracellular vesicles (MSC-EVs). Furthermore, the PIC/S GMP plant has commenced construction in early June, which will enable the production of allogeneic cell therapy products that comply with cGMP regulations. We believe that this strategic alliance with StemCyte, which has over 2,300 successful global transplantation cases, will elevate Mycenax 's cell therapy service platform to a higher level. It will provide customers with more sophisticated one-stop professional services and overcome the challenges of difficult access to raw materials and unstable quality in allogeneic immune cell therapy products.”
StemCyte stated, " In the face of the current situation where autologous cell therapy products have long preparation times and high prices, making it difficult to be widely accessible, the use of allogeneic cell therapy products produced from a sufficient and stable source of cellular raw materials has become the present market trend. The sources of cellular raw materials mainly include healthy donors, induced pluripotent stem cells (iPSCs), and umbilical cord blood. Among them, umbilical cord blood is the most promising material for allogeneic immune cell therapy production and preparation on a large scale because all the raw materials are collected and preserved at the time of birth, making it relatively stable and safe. StemCyte not only provides cellular raw materials that meet the standards of the U.S. Food and Drug Administration (FDA) and have successful case evidence, but also possesses a public donated umbilical cord blood bank resource, capable of meeting customized customer demands.
In recent years, regenerative medicine has been developing rapidly. To provide safer and more effective treatment methods, hundreds of pharmaceutical companies have entered the field of regenerative medicine. Among them, allogeneic cell therapy has emerged with the advantages of easy accessibility and scientific evidence. On Mycenax 's allogeneic cell therapy service platform, StemCyte provides cell therapy product raw materials for global customers, while Mycenax focuses on process scale-up development and GMP production. With high-quality and stable raw materials, Mycenax realizes the goal of commercializing customers' research achievements through its process scale-up technology and GMP production.
About Mycenax
Mycenax takes the CDMO brand positioning of "big D and medium M" with "Innovative development abilities (D) and Adequate manufacturing capacity (M)" to provides one-stop services for the development and manufacture of traditional biologics and novel biological drugs. At its core, Mycenax is committed to the development and production of biological drugs, from the R&D phase to cGMP manufacturing plants to drug commercialization. Mycenax, as an international CDMO company, continuously invests in product development innovations and technology platform optimizations in order to provide customers with comprehensive and streamlined CDMO services. Mycenax Biotech currently has a capital of 2.05 billion NTD (~67.2 million USD).
Stock code: Mycenax Biotech (4726).
Company website: http://www.mycenax.com.tw
Press Contact:
Stacy Sun
Email: stacy.sun@mycenax.com.tw
About StemCyte
StemCyte is the only multinational cell therapy company operating in the United States, India, and Taiwan. Over the past 20 years, StemCyte has collaborated with 350 medical centers worldwide and has successfully treated over 2,500 patients using its proprietary allogeneic cord blood cell bank resources. Additionally, the company is actively developing allogeneic cell therapy products, including one Biologics License Application (BLA) filing, two US FDA-approved Phase II clinical trials, and two TFDA-approved Phase I clinical trials currently underway.
Company website: https://www.stemcyte.com.tw/
[Taipei, June 15, 2023] Mycenax Biotech (hereinafter referred to as "Mycenax", TWO: 4726) announced today it has signed an MOU with StemCyte. StemCyte will become the cell therapy material supplier for Mycenax’s global allogeneic cell therapy CDMO business.
Mycenax, who is positioned as a "big D and medium M" CDMO, has been actively expanding into the field of cell therapy. With the signing of the MOU with StemCyte, the only multinational cell therapy company in Taiwan with its own allogeneic public cord blood bank resources, Mycenax will be able to provide customers with more sophisticated one-stop professional services in cell therapy.
Mycenax stated, "Mycenax is a CDMO company that expertise spans across both traditional and emerging biopharmaceuticals. Based on market trends and customer demands, Mycenax has developed technologies and production capabilities for both traditional and emerging biopharmaceuticals. In 2021, Mycenax established a team and laboratory dedicated to allogeneic cell therapy, focusing on advanced process development services for allogeneic stem cells and immune cells. The cell product categories include mesenchymal stem cells, chimeric antigen receptor natural killer cells (CAR-NK), gamma delta T cells (GDT), and mesenchymal stem cell-derived extracellular vesicles (MSC-EVs). Furthermore, the PIC/S GMP plant has commenced construction in early June, which will enable the production of allogeneic cell therapy products that comply with cGMP regulations. We believe that this strategic alliance with StemCyte, which has over 2,300 successful global transplantation cases, will elevate Mycenax 's cell therapy service platform to a higher level. It will provide customers with more sophisticated one-stop professional services and overcome the challenges of difficult access to raw materials and unstable quality in allogeneic immune cell therapy products.”
StemCyte stated, " In the face of the current situation where autologous cell therapy products have long preparation times and high prices, making it difficult to be widely accessible, the use of allogeneic cell therapy products produced from a sufficient and stable source of cellular raw materials has become the present market trend. The sources of cellular raw materials mainly include healthy donors, induced pluripotent stem cells (iPSCs), and umbilical cord blood. Among them, umbilical cord blood is the most promising material for allogeneic immune cell therapy production and preparation on a large scale because all the raw materials are collected and preserved at the time of birth, making it relatively stable and safe. StemCyte not only provides cellular raw materials that meet the standards of the U.S. Food and Drug Administration (FDA) and have successful case evidence, but also possesses a public donated umbilical cord blood bank resource, capable of meeting customized customer demands.
In recent years, regenerative medicine has been developing rapidly. To provide safer and more effective treatment methods, hundreds of pharmaceutical companies have entered the field of regenerative medicine. Among them, allogeneic cell therapy has emerged with the advantages of easy accessibility and scientific evidence. On Mycenax 's allogeneic cell therapy service platform, StemCyte provides cell therapy product raw materials for global customers, while Mycenax focuses on process scale-up development and GMP production. With high-quality and stable raw materials, Mycenax realizes the goal of commercializing customers' research achievements through its process scale-up technology and GMP production.
About Mycenax
Mycenax takes the CDMO brand positioning of "big D and medium M" with "Innovative development abilities (D) and Adequate manufacturing capacity (M)" to provides one-stop services for the development and manufacture of traditional biologics and novel biological drugs. At its core, Mycenax is committed to the development and production of biological drugs, from the R&D phase to cGMP manufacturing plants to drug commercialization. Mycenax, as an international CDMO company, continuously invests in product development innovations and technology platform optimizations in order to provide customers with comprehensive and streamlined CDMO services. Mycenax Biotech currently has a capital of 2.05 billion NTD (~67.2 million USD).
Stock code: Mycenax Biotech (4726).
Company website: http://www.mycenax.com.tw
Press Contact:
Stacy Sun
Email: stacy.sun@mycenax.com.tw
About StemCyte
StemCyte is the only multinational cell therapy company operating in the United States, India, and Taiwan. Over the past 20 years, StemCyte has collaborated with 350 medical centers worldwide and has successfully treated over 2,500 patients using its proprietary allogeneic cord blood cell bank resources. Additionally, the company is actively developing allogeneic cell therapy products, including one Biologics License Application (BLA) filing, two US FDA-approved Phase II clinical trials, and two TFDA-approved Phase I clinical trials currently underway.
Company website: https://www.stemcyte.com.tw/